AKANNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31

AKANDA CORP.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Jun 9, 2026

$1.12−0.08 (-6.67%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

AKANDA CORP. income statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Revenue	0.26	0.84	0.42	2.62	0.04	0.00	–
Cost of Revenue	0.41	0.63	0.36	0.57	0.04	0.00	–
Gross Profit	-0.16	0.21	0.06	3.27	0.00	-0.06	–
Selling & Marketing	3.50	–	–	–	–	–	–
Advertising Expenses	2.14	0.72	–	–	–	–	–
Operating Expenses	4.83	4.03	3.72	23	–	–	–
Operating Income	-4.98	-4.03	-3.66	-20	-2.57	-1.67	-0.90
Interest Expense	0.93	0.08	0.12	0.12	0.01	0.65	0.49
Interest & Investment Income	–	0.00	0.00	0.00	0.00	0.01	0.00
Asset Impairment Charges	–	–	8.73	–	–	–	–
Pretax Income	-47	-4.10	–	–	–	–	–
Income from Continuing Operations	-47	-3.31	-3.71	-8.24	-2.47	–	–
Income from Discontinued Operations	0.51	-0.78	-29	-3.42	-5.66	–	–
Net Income incl. Noncontrolling Interests	-46	-4.10	-32	-12	-8.13	-2.30	-1.39
Minority Interest in Earnings	-47	-4.10	–	–	–	–	–
Net Income	-1.21	–	–	–	–	–	–
EPS (Basic)(per share)	-662.22	-276.40	-573.11	-308.80	-400.00	-144.00	-88.00
EPS (Diluted)(per share)	-662.22	-276.40	-573.11	-308.80	-400.00	-144.00	-88.00
Shares Outstanding (Basic, Weighted)(shares)	0.03	0.01	0.06	0.04	0.02	0.02	0.02
Shares Outstanding (Diluted, Weighted)(shares)	0.03	1.04	0.06	0.04	0.02	0.02	0.02
EBITDA	-4.55	-3.89	-3.45	-16	-2.26	-1.42	-0.70

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: -60.5%
Operating margin: -1931.0%
Net margin: -467.1%
Return on equity, FY2025: –

Financial strength

Current ratio: 0.22
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 6.1%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –